IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces three new biopharma contracts and the appointment of Lammert Albers as Chief Business Officer effective immediately.
The new contracts are:
· A start up agreement with a new client for a new multi-study programme in Progressive Supranuclear Palsy (PSP), with an initial value of c£0.4 million, over 12 months
· A c£0.35 million, three-year, expansion of an existing study to add a significant patient cohort in China
· A c£0.45 million, two-year, new client contract to support a Phase IV study for a US biotech client, exploring a new application for a marketed drug for mental health
The Company has been contracted to initiate work on a new PSP programme for a client, ahead of patient enrolment later in 2019. The first study in the programme has a value of approximately £0.4 million and is expected to lead to a larger programme of work in early 2020.